Trial outcomes and the methodological quality of each trial were independently assessed by the 2 reviewers. The superiority of HCSE is suggested by all placebo-controlled studies. The use of HCSE is associated with a decrease of the lower-leg volume and a reduction in leg circumference at the calf and ankle. Symptoms such as leg pain, pruritus, and a feeling of fatigue and tenseness are reduced. One trial suggests a therapeutic equivalence of HCSE and compression therapy.
Adverse effects are usually mild and infrequent.
Thus, HCSE represents a treatment option for CVI that is worth considering. Accepted for publication April 22, 1998. All rights reserved.